Pfizer’s Blood Cancer Therapy Adcetris Succeeds In Late-Stage Trial
Pfizer, said on Tuesday its drug, Adcetris, extended survival in patients with the most common type of lymphoma in a late-stage study, bolstering efforts to expand the use of the treatment gained through its $43 billion purchase of Seagen.…